



SUPPLEMENTARY INFORMATION

Figure S1. Estimated probability of COPD according to pack-years



Estimated probability of COPD (y-scale) according to pack-years (x-scale) after adjustment for age, sex, BMI and eosinophil percentage.

Figure S2. Characteristics of cases with current asthma and clinical COPD



Proportion of symptomatic cases with or without diagnosis and / or respiratory medication use in current asthma (A) and clinical COPD (B). In both current asthma and clinical COPD, 1 subject did not fill in the ECRHS3 questionnaire and they were classified in the figure as if they did not have respiratory symptoms.

Table S1. Characteristics of COPD cases stratified by >10 pack-years and ≤10 pack-years of smoking history

Subject characteristics	COPD ≤10 pack-years (n=107)	COPD >10 pack-years (n=99)	P
Age (year)	56.0 ± 6.0	58.7 ± 4.9	0.001
Male (%)	62 (57.9%)	68 (68.7%)	0.110
Higher education	44 (41.1%)	35 (36.1%)	0.461
Clinical COPD	42 (39.3%)	62 (62.6%)	
Lung function			
Current respiratory symptoms (%)	36 (33.6%)	60 (60.6%)	<0.001
FEV1 percent predicted (%)	93.1 ± 15.1	81.0 ± 19.2	<0.001
FVC percent predicted (%)	111.3 ± 17.6	99.4 ± 18.0	<0.001
FEV1/FVC (%)	65.8 ± 4.5	63.1 ± 6.9	0.001
Characteristics of metabolic syndrome			
BMI (kg/m ²)	25.7 ± 3.7	25.8 ± 4.2	0.856
Systolic blood pressure (mmHg)	129.7 ± 13.2	129.0 ± 16.6	0.720
Diastolic blood pressure (mmHg)	81.7 ± 9.4	78.5 ± 10.7	0.024
Total cholesterol (mg/dL)	210.5 ± 33.0	198.8 ± 42.3	0.026
Triglycerides (mg/dL)	81.0 (60.0-118.0)	93.5 (69.0-127.3)	0.058
Glycaemia (mg/dL)	93.9 ± 10.4	99.3 ± 16.2	0.005
Inflammatory parameters			
High sensitive CRP (mg/L)	0.85 (0.46-1.83)	1.03 (0.54-2.03)	0.289
White blood cell count (10 ⁹ /L)	6.7 ± 1.8	7.5 ± 2.1	0.002
Eosinophils percentage (%)	2.2 (1.3-3.4)	2.3 (1.6-3.4)	0.450
Comorbidities			
Arterial hypertension	46 (43.0%)	49 (49.5%)	0.349
Overweight (BMI≥25 and<30 kg/m ²)	45 (42.1%)	40 (40.4%)	0.810
Obese (BMI≥30 kg/m ²)	11 (10.3%)	12 (12.1%)	0.675
Type 2 diabetes	4 (3.7%)	11 (11.1%)	0.042
Mild renal function impairment (eGFR 60-89)	73 (68.2%)	58 (58.6%)	0.151
Moderate to severe renal function impairment (eGFR<60)	5 (4.7%)	3 (3.0%)	0.542
Atopy	24 (24.7%)	11 (12.1%)	0.026
Laboratory parameters			
eGFR (ml/min/1.73m ²)	84.2 ± 17.0	85.7 ± 15.8	0.523
Creatinine (mg/dL)	9.1 ± 1.7	9.1 ± 1.8	0.834
Microalbuminuria (mg/L)	6.1 (4.1-9.0)	6.6 (4.5-11.7)	0.138
Hematocrit (%)	41.7 ± 2.9	42.7 ± 3.0	0.016
Thrombocytes (10 ⁹ /L)	245.4 ± 49.0	246.7 ± 52.5	0.858
Respiratory medication			
Respiratory medication use	9 (8.4%)	21 (21.2%)	0.009
Self-reported respiratory medication use	9 (8.7%)	20 (20.8%)	0.015
GP reported respiratory medication use (ATC R03):	5 (4.7%):	14 (14.1%):	0.019
ICS	4 (3.7%)	12 (12.1%)	0.025
LABA	4 (3.7%)	13 (13.1%)	0.014
LAMA	1 (0.9%)	1 (1.0%)	0.956
Other medication			
Oral corticosteroids (ATC H02)	0 (0.0%)	3 (3.0%)	N.A.
Oral anti-histaminica (ATC H06)	3 (2.8%)	1 (1.0%)	0.351

Manuscript submission template:

SABA = short-acting beta-agonist, LABA = long-acting beta-agonist, LAMA = long-acting muscarinic antagonist, ICS = inhalation corticosteroids, OCS = oral corticosteroids, N.A. = not applicable.